iSpecimen stock analysis
Want to see ISPC full AI Analyst Report?
iSpecimen (ISPC) Stock Price & Analysis
ISPC Stock Chart & Stats
- Day’s Range
- $0.56 - $0.60
- 52-Week Range
- $0.56 - $27.45
- Previous Close
- $0.60
- Volume
- N/A
- Average Volume (3M)
- 212.70K
- Market Cap
- $3.45M
- Enterprise Value
- -$478.08K
- Total Cash (Recent Filing)
- $4.41M
- Total Debt (Recent Filing)
- $240.90K
- Price to Earnings (P/E)
- ―
- Beta
- 1.49
- Next Earnings
- Mar 17, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Low debt relative to equity reduces near-term interest and repayment pressure, giving iSpecimen more flexibility than a highly leveraged company. This cushion could help management fund operations or strategic initiatives while it works to improve weak earnings and cash generation.
AI Capability Expansion
Adding disease-intelligence software and models broadens iSpecimen beyond biospecimen fulfillment and could increase the usefulness of its healthcare network. If integrated effectively, the combined offering may support higher-value research workflows and create additional commercial opportunities.
Biospecimen Marketplace Model
A platform connecting specimen providers with multiple research customer groups can address a specialized sourcing problem while supporting repeat transactions and data-enabled services. The model also gives iSpecimen a basis for combining biospecimens, logistics, compliance, and clinical information.
Bears Say
Revenue And Margin Collapse
Sharp revenue deterioration combined with negative gross profit indicates that current service economics are not covering the cost of delivery. Unless the trend reverses, weak scale and unfavorable margins can limit reinvestment, erode operating leverage, and prolong dependence on external capital.
Persistent Cash Burn
Ongoing operating and free-cash-flow losses show that the business is consuming cash rather than funding itself. This reduces financial resilience and leaves iSpecimen reliant on financing or other capital access to sustain operations, pursue growth, and absorb continued execution setbacks.
Dilution And Listing Risk
The company’s need for equity-linked financing can dilute existing holders and may reflect limited internal funding capacity. At the same time, unresolved Nasdaq equity compliance creates a structural corporate risk, because failure to meet requirements could impair access to public capital markets.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
What is iSpecimen’s market cap?
When is iSpecimen’s upcoming earnings report date?
How were iSpecimen’s earnings last quarter?
Is iSpecimen overvalued?
Does iSpecimen pay dividends?
What is iSpecimen’s EPS estimate?
How many shares outstanding does iSpecimen have?
What happened to iSpecimen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of iSpecimen?
What is the TipRanks Smart Score and how is it calculated?
Company Description
iSpecimen
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Shahin Behroyan
- Employees
- 7
- Website
- ispecimen.com
- Address
- 8 Cabot Road, Woburn, MA, 01801, US
iSpecimen (ISPC) Earnings & Revenues
ISPC Earnings Call
Earnings Call SentimentPositive
The earnings call highlighted strong revenue growth and significant operational improvements, particularly with the successful Next Day Quote program. However, challenges such as increased costs and a decrease in specimen count were noted. Despite some challenges, the overall tone was optimistic about future growth.
View all ISPC earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |










